2 min read
ASCO Annual Meeting
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to...
3 min read
August 2019 Updates from FDA
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided in August 2019.
FDA Updates
FDA has Finalized the Following Draft Guidance Documents:
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry (Published 28Aug2019)
https://www.fda.gov/media/130326/download
Osteoporosis: Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry (14Aug2019)
https://www.fda.gov/media/129899/download
Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry (13Aug2019)
https://www.fda.gov/media/129881/download
Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry (01Aug2019)
https://www.fda.gov/media/129547/download
Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry (31Jul2019)
https://www.fda.gov/media/129530/download
Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry (31Jul2019)
https://www.fda.gov/media/129531/download
Vulvovaginal Candidiasis: Developing Drugs for Treatment Guidance for Industry (31Jul2019)
https://www.fda.gov/media/129537/download
FDA has Issued the Following New Draft Guidance Documents:
Male Breast Cancer: Developing Drugs for Treatment Guidance for Industry (Published 27Aug2019)
https://www.fda.gov/media/130061/download
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry (13Aug2019)
https://www.fda.gov/media/129880/download
Fabry Disease: Developing Drugs for Treatment Guidance for Industry (07Aug2019)
https://www.fda.gov/media/129690/download
E8(R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES (31Jul2019)
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry (31Jul2019)
https://www.fda.gov/media/129532/download
Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers Guidance for Industry (31Jul2019)
https://www.fda.gov/media/129533/download
FDA In The News:
FDA Probe Into Patient Infections Over Contaminated Duodenoscopes Hits Turning Point (Published 30Aug2019)
EMA Offers Edits on FDA Draft Guidance on Biosimilars (Published 29Aug2019)
WHO Launches Registry for Gene Editing Studies (29Aug2019)
EU Regulatory Roundup: AstraZeneca Gets Clearance to Export Calquence API to EU in No-Deal Brexit (Published 29Aug2019)
EC Cites Regulatory Controls for Medical Devices as US-EU Trade Barriers (published 07Aug2019)
Updated: FDA Reviewing Data Manipulation in Application for Novartis Gene Therapy Zolgensma (Published 06Aug2019)
eCTD Submission Management (05Aug2019)
https://www.raps.org/news-and-articles/news-articles/2019/8/ectd-submission-management
FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient’s Voice in Medical Product Development and Regulatory Decision Making (Published August 2019)
Global public meeting on draft ICH guideline on clinical trials (Published 30Aug2019)
https://www.ema.europa.eu/en/news/global-public-meeting-draft-ich-guideline-clinical-trials
FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. FDA Drug Safety Communication (Published 28Aug2019)
Just the Stats, Ma’am: FDA Increases Inspections in Foreign Countries, Resulting in a Higher Rate of Enforcement Actions than Imposed on U.S. Facilities (Published 30Aug2019)
Laser-charged gold nanoparticles destroy prostate tumors in first-in-human study (Published 29Aug2019)
EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US (Published 16Aug2019)
Supporting medicine developers in generating quality data packages in early access approaches (PRIME and breakthrough therapies): workshop report published (Published 31Jul2019)
Brexit-related guidance for companies
https://www.ema.europa.eu/en/about-us/uks-withdrawal-eu/brexit-related-guidance-companies
- Download our most recent Infographic explaining the Types of FDA Meetings with CDER and CBER
- Regulatory Affairs
- Regulatory Consulting
- Regulatory Approvals
- Agency Meetings Support
- Regulatory Publishing